Guggenheim assumed coverage of Kymera Therapeutics (KYMR) with a Buy rating and $90 price target The firm sees a good stock setup into KT-621 Phase 1b atopic dermatitis data disclosure in Q4. Kymera has collected enough information in the first 10 of 20 patients to launch the Phase 2 in October before the Phase 1b completed, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- KYMR Upcoming Earnings Report: What to Expect?
- Kymera Therapeutics price target raised to $72 from $54 at BofA
- Kymera Therapeutics’ KT-579 Shows Promising Preclinical Results, Earning Buy Rating from Analyst
- Kymera Therapeutics Advances KT-621 Study for Atopic Dermatitis
- Kymera Therapeutics presents new preclinical data for KT-579